# Nuclide record alphamedix (drug). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/drugs/alphamedix/>
  a schema:Drug ;
  nuclide:kind "drug" ;
  schema:identifier "alphamedix" ;
  schema:name "212Pb-DOTAMTATE"@en ;
  schema:description "An alpha-particle version of neuroendocrine radioligand therapy that produced responses in over half of patients who had never had PRRT, with FDA Breakthrough designation."@en ;
  schema:url <https://nuclide.cc/drugs/alphamedix/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://www.sanofi.com/en/media-room/press-releases/2025/2025-10-08-05-00-00-3163053> ;
  nuclide:status "phase-2" ;
  nuclide:modality "Targeted alpha therapy (lead-212)" ;
  schema:alternateName "AlphaMedix" ;
  nuclide:related <https://nuclide.cc/isotopes/pb-212/> ;
  nuclide:indications <https://nuclide.cc/indications/neuroendocrine/> ;
  nuclide:technologies <https://nuclide.cc/technologies/prrt/>, <https://nuclide.cc/technologies/targeted-alpha-therapy/> ;
  nuclide:targets <https://nuclide.cc/targets/sstr2/> ;
  nuclide:companies <https://nuclide.cc/companies/orano-med/>, <https://nuclide.cc/companies/radiomedix/> ;
  nuclide:trials <https://nuclide.cc/trials/alphamedix-02/> .